Clinical Trials in Pittsburgh

Showing 13841-13860 of 21,047 trials

Hemophilia B Gene Therapy With AAV8 Vector

NCT01620801

Hemophilia B is a bleeding disease in males due to very low levels of coagulation factor IX (FIX) in the blood. The current treatment is intravenous injection of FIX clotting factor concentrates, in response to bleeding. This study will focus on the severe, most common type of hemophilia B. This study plans to use a virus called adeno-associated virus (AAV), which in nature causes no disease, and can be engineered to deliver the human FIX gene (AAV8-hFIX19 vector) to liver cells, where FIX is normally made. This study will use the AAV8-hFIX19 vector.

Hemophilia B

Spark Therapeutics, Inc.4 participantsStarted Oct 2012

Philadelphia, Pennsylvania, United States • Pittsburgh, Pennsylvania, United States • Camperdown, New South Wales, Australia

COMPLETEDPhase 2< 1 mile

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

NCT01233375

The purpose of this study is to determine whether CO-1.01 is safe and effective for treating metastatic pancreatic cancer that did not respond to gemcitabine.

Metastatic Pancreatic Adenocarcinoma

Clovis Oncology, Inc.19 participantsStarted Apr 2011

Tucson, Arizona, United States • Denver, Colorado, United States • Boynton Beach, Florida, United States +10 more locations

Hemophilia B Gene Therapy With AAV8 Vector

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

Find Trials by Condition in Pittsburgh

Lung Tissue Research Consortium

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

Inflammation and the Host Response to Injury (Trauma)

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c

Nurse and Physician Stress Reduction: Learning Receptive Awareness Via EEG Feedback

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients

Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE)

HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids

Multicenter Benchmarking of Functional and Psychosocial Outcomes of Pediatric Burn Survivors

Validation of Non-Invasive Intracranial Pressure (ICP) Monitoring Device

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation